8-K: Monogram Orthopaedics Updates Stock Purchase Agreement and NVIDIA Program Status

Monogram Orthopaedics has updated its stock purchase agreement with B. Riley Principal Capital II and clarified its status with the NVIDIA Inception Program.

Summary

• Monogram Orthopaedics has a stock purchase agreement with B. Riley Principal Capital II, allowing them to sell up to $20 million of common stock or 5,847,725 shares, whichever is less.
• The company has the sole discretion to sell shares and is not obligated to do so.
• A resale registration statement was filed and declared effective, initially covering 6,500,000 shares, which was later amended to 6,243,974 shares after the annual report.
• As of April 18, 2024, Monogram has issued 256,026 shares for gross proceeds of $887,831.
• Monogram's application to the NVIDIA Inception Program was initially approved but later rescinded because the company is publicly traded.
• Monogram intends to apply to the NVIDIA Developer Program instead.

Sentiment

Score: 6

Explanation: The news is mixed, with a positive capital raising option but a setback with the NVIDIA program. The company is actively addressing the issues, which is a positive sign.

Positives

• Monogram has access to a stock purchase agreement with B. Riley Principal Capital II for potential capital raising.
• The company has successfully sold some shares and generated gross proceeds of $887,831.
• Monogram is actively pursuing alternative programs with NVIDIA after the initial program was rescinded.

Negatives

• The NVIDIA Inception Program application was rescinded, which may have been a setback for the company's plans.
• The company has only sold a small portion of the available shares under the purchase agreement.

Risks

• The company's ability to raise capital through the stock purchase agreement is dependent on market conditions and their discretion.
• The NVIDIA program change may delay or alter the company's technology development plans.
• There is no guarantee that the company will be accepted into the NVIDIA Developer Program.

Future Outlook

Monogram intends to pursue the NVIDIA Developer Program after being removed from the Inception Program.

Management Comments

• The company has the sole discretion to sell shares under the purchase agreement.
• The company was unaware of the public company restriction for the NVIDIA Inception Program at the time of application.

Industry Context

The use of NVIDIA programs suggests Monogram is focused on leveraging advanced computing for its orthopaedic solutions, aligning with the trend of technology integration in healthcare.

Comparison to Industry Standards

• The stock purchase agreement with B. Riley is a common method for small-cap companies to raise capital.
• The NVIDIA Inception Program is designed for startups, so Monogram's ineligibility as a public company is consistent with the program's criteria.
• Other medical device companies are also exploring AI and advanced computing, making Monogram's pursuit of the NVIDIA Developer Program relevant.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the sale of new shares.
• The NVIDIA program change may affect the company's technology development timeline.

Next Steps

• Monogram intends to apply to the NVIDIA Developer Program.
• The company may continue to sell shares under the stock purchase agreement.

Key Dates

Keywords

stock purchase agreement, capital raise, NVIDIA, common stock, resale registration, B. Riley Principal Capital II, developer program, Inception Program